IASO BIOTHERAPEUTICS
IASO Biotherapeutics (IASO BIO) is a Nanjing-based biopharmaceutical company focused on the discovery, development and commercialization of cell therapies in the field of oncology.
IASO BIOTHERAPEUTICS
Industry:
Biotechnology Pharmaceutical
Founded:
2017-01-01
Address:
Nanjing, Jiangsu, China
Country:
China
Website Url:
http://www.iasobio.com
Total Employee:
251+
Status:
Active
Contact:
025-58287610
Email Addresses:
[email protected]
Total Funding:
168 M USD
Technology used in webpage:
SPF Apache Euro Microsoft Azure DNS PHP Apache 2.4 OpenSSL GlobalSign HiChina DNS Win32 Header
Similar Organizations
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Dunad Therapeutics
Dunad Therapeutics is a biopharmaceutical company focusing on the development of next-generation targeted protein degradation therapies.
Immutep
Immutep is a biopharmaceutical company developing immunotherapeutics in oncology.
MRM Health NV
MRM Health NV is a biopharmaceutical company focused on the discovery and development of therapeutics based on the human microbiome.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Sirnaomics
Sirnaomics is a biopharmaceutical company developing therapeutics for critical human diseases by using RNA interference technology.
WeHand
WeHand is a biopharmaceutical company focusing on the development of hypoglycemic drugs.
Current Employees Featured
Founder
Investors List
Co-Stone Venture Capital
Co-Stone Venture Capital investment in Series C - IASO Biotherapeutics
Everbright
Everbright investment in Series C - IASO Biotherapeutics
CCB International
CCB International investment in Series C - IASO Biotherapeutics
Plaisance Capital
Plaisance Capital investment in Series C - IASO Biotherapeutics
CDH Investments
CDH Investments investment in Series C - IASO Biotherapeutics
GL Ventures
GL Ventures investment in Series C - IASO Biotherapeutics
CNCB Capital
CNCB Capital investment in Series C - IASO Biotherapeutics
Hillhouse Capital Group
Hillhouse Capital Group investment in Series B - IASO Biotherapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2021-10-19 | IASO Bio Appoints Industry Veteran Dr. Alan Fu Chief Financial Officer |
Official Site Inspections
http://www.iasobio.com
- Host name: 120.133.2.80
- IP address: 120.133.2.80
- Location: China
- Latitude: 34.7725
- Longitude: 113.7266
- Timezone: Asia/Shanghai
